| Issue Date |
Title |
Author(s) |
| 2006 |
Fabrication of ZnO nanowires by vapor-phase deposition and their field emission properties |
Zhang, Qifeng;Rong, Yi;Chen, Xianxiang;Zhang, Gengmin;Zhang, Zhaoxiang;Xue, Zengquan;Chen, Changqi;Wu, Jinlei |
| Aug-2021 |
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial |
Zhao, Hong;Zhang, Chi;Zhu, Qi;Chen, Xianxiang;Chen, Guilin;Sun, Wenjin;Xiao, Zuohan;Du, Weijun;Yao, Jing;Li, Guojun;Ji, Yanhua;Li, Niuniu;Jiang, Yujin;Wang, Ying;Zeng, Qingjin;Li, Wei;Gong, Beilei;Chang, Xianyou;Zhu, Feng;Jiang, Xiufeng;Li, Jiawen;Wu, Zhao;Liu, Yingxia;Peng, Peng;Wang, Guiqiang |
| 2004 |
Influence of annealing on field emission properties of zinc oxide nanowires |
Chen, Xianxiang;Zhang, Qifeng;Zheng, Wenfeng;Zhang, Zhaoxing;Zhang, Gengmin;Zhao, Xingyu;Chen, Changqi;Xue, Zengquan;Wu, Jinlei |
| Mar-2021 |
Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status |
Zhou, Yonggang;Zhang, Jinhe;Wang, Dongyao;Wang, Dong;Guan, Wuxiang;Qin, Jingkun;Xu, Xiuxiu;Fang, Jingwen;Fu, Binqing;Zheng, Xiaohu;Wang, Dongsheng;Zhao, Hong;Chen, Xianxiang;Tian, Zhigang;Xu, Xiaoling;Wang, Guiqiang;Wei, Haiming |
| Jan-2021 |
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size |
Zhao, Hong;Zhu, Qi;Zhang, Chi;Li, Jiawen;Wei, Ming;Qin, Yuhong;Chen, Guilin;Wang, Ke;Yu, Junhua;Wu, Zhao;Chen, Xianxiang;Wang, Guiqiang |
| Oct-2021 |
Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA |
Wang, Dongyao;Wang, Dong;Huang, Min;Zheng, Xiaohu;Shen, Yiqing;Fu, Binqing;Zhao, Hong;Chen, Xianxiang;Peng, Peng;Zhu, Qi;Zhou, Yonggang;Zhang, Jinghe;Tian, Zhigang;Guan, Wuxiang;Wang, Guiqiang;Wei, Haiming |
